Bionentus is a global medical device holding company focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and improve the body's natural healing process. Co.'s portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, which is comprised of non-surgical joint pain injection therapies as well as peripheral nerve stimulation products; Surgical Solutions, which is comprised of bone graft substitutes to fuse and grow bones, improve results following spinal and other orthopedic surgeries; and Restorative Therapies, which is comprised of an Ultrasonic bone healing system, among others. The BVS average annual return since 2021 is shown above.
The Average Annual Return on the BVS average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BVS average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BVS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|